Medicines that we take only a few times and which permanently alter the trajectory of our lives for the better, are on the way.

Eli Lilly said a base editing gene therapy from its purchase of Verve Therapeutics delivered additional positive results in a Phase 1b trial, paving the way for a mid-stage test…

Medicines that we take only a few times and which permanently alter the trajectory of our lives for the better, are on the way.